Welcome Guest! You are here: Home » Health
Sub-standard medicines: Plea in SC seeks action against Ranbaxy
Wednesday June 5, 2013 9:49 PM , IANS

The Supreme Court was moved Wednesday for a direction to the centre to cancel the manufacturing licences of pharma major Ranbaxy and its group companies for allegedly marketing sub-standard medicines.

Petitioner Manohar Lal Sharma, an advocate, sought direction to order closure of Ranbaxy manufacturing units located in Ponta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh and other places under Section 18 the Drugs and Cosmetics Act 1947.

Seeking direction to the Central Bureau of Investigation to initiate a probe into the alleged supply of sub-standard medicines and proceed against all the former and the present directors of Ranbaxy, the public interest litigation sought directions to restrain the drug manufacturing company from marketing its medicines in India.

The petitioner sought direction to seize property of all the present and former directors of Ranbaxy as allegedly manufacturing and selling adulterated and spurious drugs.

The petitioner said that the allegation of Ranbaxy marketing sub-standard medicine had already been proved in the US.

Share this page
Note: By posting your comments here you agree to the terms and conditions of www.ummid.com
comments powered by Disqus
| Quick links
About ummid.com
Contact us
Subscribe to: RSS » Facebook » Twitter » Newsletter
Ummid.com: Disclaimer | Terms of Use | Advertise with us | Link Exchange
Ummid.com is part of the Awaz Multimedia & Publications providing World News, News Analysis and Feature Articles on Education, Health. Politics, Technology, Sports, Entertainment, Industry etc. The articles or the views displayed on this website are for public information and in no way describe the editorial views. The users are entitled to use this site subject to the terms and conditions mentioned.
© 2012 Awaz Multimedia & Publications. All rights reserved.